BioNTech Price Target Cut at Citi Following Co-Founder NewsIn a notable development for shareholders of the German biotechnology giant, Citi has revised its financial outlook for BioNTech SE (NASDAQ: BNTX) . The financial services firm announced it is lowering its price target on the company's shares to $130 from $145 , a reduction of approximately 10%. Des
BioNTech SE ADR Unsponsored Brazilian Depositary Receipt Repr 0.0625 ADR
No trades
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−28.727 BRL
−7.04 B BRL
17.79 B BRL
250.39 M
About BioNTech SE
Sector
Industry
CEO
Ugur Sahin
Website
Headquarters
Mainz
Founded
2008
IPO date
Oct 10, 2019
Identifiers
2
ISIN BRB1NTBDR005
BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.
Related stocks
$BNTX The Founders Left. The Pipeline Didn't.This morning BioNTech dropped a bombshell. Co-founders Prof. Ugur Sahin and Prof.
Özlem Türeci, the two scientists who built the mRNA platform that produced the world's first approved COVID-19 vaccine, announced they are leaving the company by end of 2026 to start a new independent mRNA-focused bi
1/7/26 - BNTX: new BUY mechanical trading signal.1/7/26 - BNTX: new BUY signal chosen by a rules based, mechanical trading system.
BNTX - BUY
Stop Loss @ 91.11
Entry BUY @ 100.08
Target Profit @ 113.80
Analysis:
Higher timeframe: Prices have stayed above the lower channel line of the ATR (Average True Range) Keltner Channel and reversed.
High
Long Thesis on BioNTech SE Post-EarningsBioNTech SE presents a compelling long opportunity following its latest earnings report. The company continues to expand beyond COVID-19 vaccines, with a strong pipeline in personalized mRNA cancer therapies, infectious disease vaccines (HIV, tuberculosis, malaria), and autoimmunity treatments. With
BNTX BioN Tech Options Ahead of EarningsAnalyzing the options chain and the chart patterns of BNTX BioN Tech prior to the earnings report this week,
I would consider purchasing the $115usd strike price Calls with
an expiration date of 2025-9-19,
for a premium of approximately $17.40.
If these options prove to be profitable prior to the ea
See all ideas
Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.









